Meet the company on a mission to reengineer drug development
Drug development is costly, time consuming, and fraught with risks. Most agree that AI is part of the solution, but translation rates have been underwhelming. One company is determined to change this, and its cell simulation platform is already being used to predict unseen biology by big pharma and smaller biotechs alike.
